All lobbying filings

THE UNITED STATES PHARMACOPEIAL CONVENTION

Lobbying for THE UNITED STATES PHARMACOPEIAL CONVENTION

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Maryland · House · Senate · $120,000.00 expenses · posted Jul 20, 2026

Official filing document

Bills named in this filing 8

S 1784
MAPS Act
HR 4191
MAPS Act
S 3788
CLEAR LABELS Act
HR 5304
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
S 2587
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
HR 4779
National Security, Department of State, and Related Programs Appropriations Act, 2026
S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 8800
National Defense Authorization Act for Fiscal Year 2027

Lobbying activity 3

Health Issues

S. 1784, H.R. 4191 - Mapping America's Pharmaceutical Supply (MAPS) Act - Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling. Issues related to strengthening the resiliency of the U.S. medical supply chain.

Budget/Appropriations

H.R. 5304, S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience. H.R. 4779 - National Security, Department of State, and Related Programs Appropriations Act, 2026: Provisions related to pharmaceutical supply chain resilience.

Defense

S. 2296 - National Defense Authorization Act for Fiscal Year 2026; H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027: Provisions related to supply chain resilience.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.